BioCentury | Jul 21, 2020
Product Development

First inhaled interferon COVID-19 readout bolsters case for class, but more robust data needed

Data suggesting an inhaled IFNB1 product from Synairgen can reduce the chance a patient with COVID-19 develops severe disease gave a jolt to the biotech’s shares Monday, but more statistically robust data are still needed...
BioCentury | Nov 1, 2019
Product Development

Novartis, Merck KGaA see opportunity in select pockets of MS patients

As companies continue to pile into the multiple sclerosis market with new therapies, Novartis and Merck KGaA are dissecting the landscape to define populations for their newly launched drugs. While the former is staking out...
BC Extra | Dec 8, 2017
Company News

Novo, Prime in outcomes-based Victoza contract

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) signed an outcomes-based contract with PBM Prime Therapeutics LLC (Eagan, Minn.) for Type II diabetes drug Victoza liraglutide under Prime's CareCentered Contract Program. Prime did not answer inquiries about the...
BioCentury | Apr 7, 2017
Finance

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BC Extra | Jan 27, 2017
Financial News

ICER finds Lemtrada most cost-effective in MS

In an evidence report evaluating disease-modifying therapies for multiple sclerosis, the Institute for Clinical and Economic Review said Lemtrada alemtuzumab from Sanofi (Euronext:SAN; NYSE:SNY) "consistently demonstrated improved health outcomes and good value" at a lower...
BC Week In Review | Oct 24, 2016
Clinical News

Cladribine tablets: Phase III data

Merck reported data from an open-label maintenance period in 109 patients who converted to clinically definite MS after treatment in the double-blind, placebo-controlled international Phase III ORACLE-MS trial evaluating once-daily 3.5 and 5.25 mg/kg cladribine...
BioCentury | Nov 23, 2015
Strategy

More with less

With 16 months under his belt as the new head of global R&D for Merck KGaA's biopharmaceuticals division, Luciano Rossetti has pruned the pipeline, accelerated the unit's cancer immunotherapy efforts and revived one late-stage program....
BC Week In Review | Oct 12, 2015
Clinical News

Ocrelizumab: Additional Phase III data

Additional data from the double-blind, double-dummy, international Phase III OPERA I trial in 821 RRMS patients showed that 300 mg IV ocrelizumab on day 1 and 15 of the first 24-week cycle followed by 600...
BC Week In Review | Oct 12, 2015
Clinical News

Ocrelizumab: Additional Phase III data

Additional data from the double-blind, double-dummy, international Phase III OPERA II trial in 835 RRMS patients showed that 300 mg IV ocrelizumab on day 1 and 15 of the first 24-week cycle followed by 600...
BC Extra | Oct 9, 2015
Clinical News

Roche presents detailed ocrelizumab data

Roche (SIX:ROG; OTCQX:RHHBY) announced data from two Phase III studies of ocrelizumab ( RG1594 ) showing superiority to Rebif interferon beta-1a from Merck KGaA (Xetra:MRK) to treat relapsing multiple sclerosis. The company also announced data from a...
Items per page:
1 - 10 of 361